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Leukemia (JMML): A Mimicker 




Juvenile myelomonocytic leukemia (JMML) is the most confusing mimicker 
of KMT2A-rearranged acute myeloid leukemia (AML). Clinical presentation, 
age of susceptibility (infancy or early childhood) and abnormal monocytosis are 
common clinical features. To complicate matters, JMML morphologically resemble 
acute myelomonocytic leukemia (AML M4) and distinction must be made based 
on accurate blast and promonocyte counts. As treatment significantly varies, 
AML/JMML overlap can lead to catastrophic consequences that can be avoided 
by timely management. Therefore, meticulous knowledge of JMML is essential to 
treat patients with hematologic malignancies. The pathognomic feature of JMML 
is increased infiltration of the peripheral blood, bone marrow, and viscera by 
abnormal myelomonocytic cells. Molecular diagnostics has generated substan-
tial dividends in dissecting the genetic basis of JMML. We can now molecularly 
confirm the diagnosis of JMML in approximately over 90% of patients who harbor 
driver mutations in KRAS, NRAS, PTPN11, NF1, or CBL genes. The presence of 
monosomy 7 is a classic feature of JMML that can support the diagnosis in many 
cases. On the other hand, cytogenetics and Fluorescence in situ hybridization 
analysis (FISH) are indispensable to differentiate KMT2A-rearranged AML from 
JMML. In particular, AML with t(9;11) is associated with monocytic features that 
can be easily mistaken for JMML.
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1. Introduction
JMML is a rare aggressive clonal hematopoietic neoplasm of infancy and early 
childhood that combines excessive proliferation of the granulocytic and monocytic 
lineages with dysplasia making JMML analogous to chronic myelomonocytic 
leukemia (CMML). Therefore, the current WHO classification of myeloid neo-
plasms and acute leukemia envisages JMML as an overlap myeloproliferative/
myelodysplastic neoplasm. The diagnosis of JMML is mainly based on the clinical 
presentation in combination with morphology of the peripheral blood smears and 
the molecular analysis of leukemic cells. The peripheral blood and bone marrow of 
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children with JMML may display features of both myeloproliferative and myelo-
dysplastic disorders (ie, immature and dysplastic forms), as well as cytopenias due 
to marrow infiltration and/or splenomegaly. Splenomegaly, lymphadenopathy, 
and skin rashes are common clinical features but the clinical picture of JMML can 
be somewhat non-specific. JMML is frequently confused with viral infections, 
immunodeficiency syndromes, myelodysplastic syndromes, myeloproliferative 
neoplasms or other forms of leukemia [1]. Moreover, JMML has diverse molecular 
subtypes with contrasting features and varied clinical outcomes. The broad overlap 
in clinical and laboratory features in combination with the heterogeneity of JMML 
itself made the diagnosis of JMML a hurdle to most hematologists. Consequently, 
the diagnosis of JMML almost always relies on the diagnostic criteria (Table 1). The 
chief backbone of the diagnostic criteria is the associated molecular and/or cytoge-
netic abnormalities. In particular, the genomic landscape of JMML had revolution-
ized our understanding of leukemogenesis of this greatly equivocal disease. JMML 
is a predominantly fatal disease but the clinical course can be highly variable. At 
both extremes of the disease, a third of patients follow a relatively indolent course 
while approximately 15% of cases develop AML, the so called ‘blast crisis’ [2].
2. Clinical features
• Patients present with splenomegaly, fever, thrombocytopenia, monocytosis, 
and elevated HbF.
• Leukocytosis is common in JMML, but a presenting white blood count  
<10 x 109/L is occasionally noted.
JMML diagnostic criteria
I. Clinical and hematologic features (all 4 features mandatory):
• PB monocyte count ≥1 x 109/L.
• Blast percentage in PB and BM <20%.
• Splenomegaly.
• Absence of Philadelphia chromosome (BCR/ABL1 rearrangement).
II. Genetic studies (1 finding sufficient):
• Somatic mutation in PTPN11 or KRAS or NRAS (Germ line mutations -indicating Noonan  
syndrome- need to be excluded).
• Clinical diagnosis of NF1 or NF1 mutation.
• Germ line CBL mutation and loss of heterozygosity of CBL.
III.  For patients without genetic features, besides the clinical and hematologic
features listed under I, the following criteria must be fulfilled:
• Monosomy 7 or any other chromosomal abnormality or at least 2 of the following criteria:
• Hemoglobin F increased for age.
• Myeloid or erythroid precursors on peripheral blood smear.
• GM-CSF hypersensitivity in colony assay.
• Hyperphosphorylation of STAT5.
1Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of 
myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643,544
Table 1. 
The diagnostic criteria for juvenile myelomonocytic leukemia1.
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• Anemia is generally not a leading symptom and rarely requires red blood cell 
(RBC) transfusion.
• Most patients present with evidence of infection or constitutional symptoms 
that may mimic viral infections.
• Polyclonal hypergammaglobulinemia and presence of autoantibodies.
• The hallmark of the disease is the overproduction of myelomonocytic cells 
(monocytic and granulocytic cells) that infiltrate skin and vital organs (spleen, 
liver, and lungs) leading to various clinical manifestations as follows [3]:
1. Lungs: dry cough, tachynoea and interstitial infiltrates on chest X-ray are 
signs of pulmonary infiltration.
2. Skin: Cafe-au-lait spots might be indicative of an underlying germline condi-
tions such as Neurofibromatosis type 1 (NF1) or Noonan syndrome-like 
disorder. Neurofibromas occur in patients with NF1. About 25% of patients 
have pleomorphic skin rashes in the forms of:
 ○ Eczematous eruptions (cradle cap).
 ○ Indurated raised lesions with central clearing.
 ○ Sweet syndrome.
3. Gut infiltration may predispose patients to diarrhea—sometimes with bloody 
features—and gastrointestinal infections.
4. Lymph nodes: About half of all patients have lymphadenopathy. Leukemic 
infiltrates may give rise to markedly enlarged tonsils.
5. There is generally marked splenomegaly/hepatosplenomegaly:
 ○ Hepatomegaly is generally less prominent than splenomegaly.
 ○ Approximately 7–10% of JMML patients will not have splenomegaly at 
diagnosis but virtually all patients will develop splenomegaly within 




The peripheral blood (Figure 1) is the most important specimen for diagnosis [4]. 
It typically shows leukocytosis and thrombocytopenia. The vast majority of JMML 
patients have thrombocytopenia with the exception of children with NF1- mutated 
JMML, who show platelet counts within the normal range in most cases. The median 
reported white blood cell counts are 25–30 x 109/L. The leukocytosis consists mainly 
of neutrophils, with some immature cells (e.g. promyelocytes and myelocytes) 
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and monocytes. Although most cases show a striking monocytosis, often with 
dysplastic forms, the absolute monocyte count can be <1 x 109/L. Blasts (including 
promonocytes) usually account for <5% of the white blood cells, and always <20%. 
Eosinophilia and basophilia are observed in a minority of cases. Nucleated red blood 
cells are often seen. Red blood cell changes include macrocytosis (particularly in 
patients with monosomy 7), but normocytic red blood cells are more common.
Figure 1. 
Peripheral blood of a 13 months old boy with PTPN11-mutated JMML. Photomicrograph shows leukocytosis 
with neutrophilia and monocytosis. There is left shift, toxic granulation and vacuolation. Occasional primitive 
cells (~ 2%) are present. No nucleated RBCs are seen.
Figure 2. 
Bone marrow aspirate demonstrates a hypercellular marrow (100 – Age = %normal cellularity) with left 
shift and increased myeloid and monocyte lineages. Blast count is about 4%. There is occasional evidence of 
hemophagocytosis and mild erythroid dysplastic features.
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3.2 Bone marrow
Bone marrow (Figure 2) findings are consistent with the diagnosis of JMML 
but are not per se diagnostic. However, bone marrow aspiration is necessary to 
exclude AML M4. The most consistent finding in bone marrow specimens is the 
reduced number or absence of megakaryocytes in about two third of cases. The 
bone marrow aspirate and biopsy are hypercellular with granulocytic proliferation, 
although in some patients erythroid precursors may predominate. Monocytes in 
the bone marrow are often less prominent than in the peripheral blood, generally 
accounting for 5–10% of the bone marrow cells. The marrow blasts (including pro-
monocytes) can be moderately elevated, but does not reach the level seen in acute 
leukemia (account for <20% of the bone marrow cells). Auer rods are never present. 
Dysplasia is usually minimal; however, dysgranulopoiesis (including pseudo-Pelger-
Huet neutrophils and hypogranularity) may be noted in some cases, and erythroid 
precursors may be enlarged. No specific immunophenotypic abnormalities have 
been reported in JMML.
4. Differential diagnosis
4.1 KMT2A-rearranged AML masquerading as JMML
Unlike in AML, the bone marrow in patients with JMML demonstrates no 
blockage of differentiation of myeloid elements. Rather, as is seen in chronic 
myeloid leukemia (CML), the bone marrow in JMML displays myeloid hyper-
plasia with increased production of monocytic cells along the full spectrum of 
differentiation, including blast forms, promonocytes, monocytes, and macro-
phages. The marrow blast count may be slightly elevated but in classic JMML 
it does not reach the counts seen in AML. Nevertheless, differentiating JMML 
from AML is nearly impossible on clinical grounds alone as significant hepato-
splenomegaly and respiratory failure can occur in both. Moreover, blood counts 
and hematologic features may mimic AML. This especially holds true for infants 
with the lysine methyltransferase 2A (KMT2A) rearrangements who occasionally 
present with hepatosplenomegaly and low blast count resembling JMML [5].  
A puzzling interface between KMT2A-rearranged AML and JMML therefore 
exists. Recent reports have validated the close mimicry between KMT2A-
rearranged AML and JMML [6]. Unless unveiled by cytogenetics, JMML can 
conceal the clinical diagnosis of KMT2A-rearranged AML. Age of susceptibility 
(infancy or early childhood) and abnormal monocytosis have blurred the line 
between these distinct entities. Specifically, JMML may mimic AML with t(9;11). 
t(9;11) is the most frequent molecular subtype involving the KMT2A gene 
(KMT2A-MLLT3) in AML. t(9;11)-positive AML/JMML overlap was well-char-
acterized in the medical literature [7]. Both conditions have increased immature 
monocytes and blasts. I reported a 14-month-old girl with t(9;11)-positive AML 
who died as she received JMML-directed therapy. The clinical picture, peripheral 
smear and the suboptimal blast count of only 10% had stealthily impersonated 
JMML [8].
Chromosomal rearrangements involving the KMT2A gene do not exist in the 
genomic landscape of JMML. KMT2A gene rearrangements are common genetic 
mutations in pediatric AML with an incidence of 15–25% (50–60% in children 
younger than two years). However, both KMT2A-rearranged AML and JMML share 
common morphologic features. KMT2A-rearranged AML is usually AML M4 or 
M5, and both are characterized by increased numbers of monoblasts or abnormal 
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monocytes. JMML morphologically resemble AML M4 and distinction must be 
made based on accurate blast and promonocyte counts.
Differentiating AML from JMML is vital for survival. Chemotherapy regimens 
for JMML are mainly cytoreductive as a bridge to hematopoietic stem cell transplan-
tation (HSCT) rather than curative as for AML. Therefore, any delay in establishing 
the correct diagnosis and/or administration of wrong treatment can be lethal. 
Molecular diagnosis has become the mainstay to distinguish between AML and 
JMML. Cytogenetics and FISH should be immediately performed to detect KMT2A 
gene rearrangements in every suspicious case.
4.2 JMML masquerading as RALD
JMML is closely related to RAS-associated autoimmune leukoproliferative 
disorder (RALD) [9]. RALD is a non-malignant, non-infectious leukoproliferative 
disease that resembles the autoimmune lymphoproliferative syndrome (ALPS) 
caused by mutations affecting the FAS/FASL pathway.
Similar to patients with ALPS, RALD patients present with lymphadenopathy, 
massive splenomegaly, increased circulating B cells, hypergammaglobulinemia, and 
autoimmunity. However, RALD was separated from ALPS as:
1. In contrast to ALPS, biomarkers such as CD4−/CD8− double negative T-cell 
receptor αβ (TCRαβ +) T cells and serum vitamin B12 levels are not always 
increased.
2. Germline or somatic mutations in FAS, FASL, or CASP10 are absent in RALD.
RALD is a RAS-associated somatic disorder characterized by myelomonocytic 
and lymphoid hyperplasia that shares identical somatic KRAS or NRAS mutations 
found in up to 25% of JMML patients. It is thought that RAS activation itself can 
alter selection patterns of autoreactive B cells and antibody production leading to 
autoimmune manifestations. Overlap features of both JMML and RALD include:
1. Cytopenias, lymphadenopathy, and splenomegaly.
2. Persistent absolute or relative monocytosis is a cardinal feature of RALD.
3. Bone marrow and peripheral blood smear findings overlap with those of JMML 
in children or CMML in older patients.
4. Morphologic features compatible with dysplasia, such as hyposegmented pel-
geroid neutrophils, can also be seen in RALD further obscuring the distinction 
between RALD and JMML.
5. Autoimmunity can be noted in up to 25% of children with JMML, whereas 
hypergammaglobulinemia is present in more than 50% of cases.
6. Nearly all patients with RALD meet the revised diagnostic criteria for JMML.
Distinguishing RALD from JMML can be impossible on clinical grounds alone. 
However, this distinction has an important prognostic value as RALD is character-
ized by an indolent clinical course whereas JMML can be fatal if left untreated. 
The most definitive diagnostic distinction between RALD and JMML occurs in the 
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setting of a cytogenetic abnormality (eg, monosomy 7), which excludes RALD and 
favors a malignant process. However, normal bone marrow cytogenetics has been 
reported in around 65% of JMML patients.
JMML/RALD overlap can lead to inappropriate treatment decisions. In some 
patients, RALD was misdiagnosed as JMML and vice versa. It is the author’s experi-
ence that a patient with KRAS-mutated JMML was misdiagnosed as RALD for 
many weeks until he developed full -blown JMML. It is noteworthy that RALD 
can occur as the initial presentation and transform to JMML several years later. 
Indeed, JMML/RALD represents a continuum of two different phenotypes of the 
same disorder. Although both RALD and JMML share common RAS mutations, the 
transition from RALD to JMML is caused by additional genetic or epigenetic events. 
Therefore, patients with RALD should be very closely monitored for acquisition of 
additional dysplastic, molecular, or clonal karyotypic abnormalties that may herald 
malignant transformation [10].
4.3 JMML masquerading as myeloproliferative neoplasms (MPNs)
JMML can mimic myeloproliferative malignancies with receptor tyrosine kinase 
translocations. Identification of these cases is crucial, because patients may benefit 
from receptor tyrosine kinase–targeted inhibitors.
4.4 Nonmalignant disorders mimicking JMML
• Viral infections such as human herpes virus-6 (HHV-6), parvovirus, or 
cytomegalovirus (CMV). Occasionally, patients with JMML may present with 
these viral infections in addition to their underlying hematologic malignancy. 
Differentiation between CMV-related disease and JMML in infants excreting 
CMV is sometimes difficult, because clinical and laboratory findings of CMV 
infection can overlap with those of JMML.
• Leukocyte adhesion deficiency variants.
• Wiskott Aldrich syndrome: need to be considered in male infants.
• Infantile malignant osteopetrosis (IMO): can mimic all clinical and hemato-
logical features of JMML.
• Hemophagoytic lymphohistiocytosis (HLH).
• Autoimmune diseases, including rheumatoid arthritis and systemic lupus 
erythematosus.
5. Genomics
5.1 The central role of the RAS signaling pathway
JMML is an oncogenic RAS mutant cancer where approximately 90% of patients 
carry either somatic or germline gain of function mutations in PTPN11, KRAS, 
NRAS, CBL, or NF1 genes that lead to constitutive activation of the RAS signal-
ing pathway (Figure 3). The RAS signaling pathway is a component of multi-step 
signal transduction pathway that controls the cellular proliferation, differentiation, 
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and survival. It relays extracellular stimuli such as growth factors to the nucleus 
where the response to those stimuli is executed by an induced transcriptional 
program [11].
The RAS family include the proto-oncogenes HRAS, NRAS and KRAS which 
represent a subset of a superfamily of small membrane-localized GTPases. Like 
other small GTPases, RAS proteins function as molecular switches that cycle 
between an inactive guanosine diphosphate (GDP)-bound and an active guanosine 
triphosphate (GTP)-bound conformations. RAS is activated when the receptor 
tyrosine kinases (RTKs, a large superfamily of receptors for a wide array of growth 
factors) are activated by growth factor binding leading to RTK autophosphorylation 
and the creation of docking sites for adaptor molecules like growth factor receptor-
bound protein 2 (GRB2). The amount of GTP-RAS generated is regulated by two 
opposing regulatory mechanisms [12]:
a. Guanine nucleotide exchange factors (GEFs) are necessary for the conversion 
of GDP-RAS into GTP-RAS. The Son of Sevenless (SOS) is the GEF for the RAS 
signaling pathway. SOS is recruited by the adaptor protein GRB2 in response 
to RTK activation. The binding of SOS to GBR2 localizes it to the plasma 
Figure 3. 
Illustrative representation of the RAS signaling pathway portraying the transmission of extracellular signals 
in a gear train to the nucleus. Upon stimulation, a docking site for GRB2 is created which binds to GEF 
(SOS). The GRB2-SOS interaction converts RAS-GDP to RAS-GTP. The RAS-GTP initiates a cascade of 
phosphorylations on RAF, MEK and, lastly, ERK. The phospho-ERK then translocates into the nucleus. A 
counteracting force by GAP (neurofibromin) accelerates the conversion of RAS-GTP to RAS-GDP to restrain 
the activation of the RAS signaling pathway. Mutations of RAS pathway prevent the conversion of RAS-GTP 
to RAS-GDP to induce the constitutive activation of the RAS signaling pathway, the characteristic feature of 
JMML.
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membrane, where it can activate the membrane bound RAS. Gain of function 
of the Src-homology tyrosine phosphatase 2 (SHP-2) results in activation of the 
GEFs and in this way to a continuous activation of RAS. SHP-2 is the encoded 
gene product of PTPN11, the most commonly mutated gene in JMML.
b. GTPase activating proteins (GAPs), like neurofibromin act antagonistically 
to inactivate RAS by increasing their intrinsic rate of GTP hydrolysis to the 
inactive form (RAS-GDP) leading to the termination of the RAS signaling. 
Neurofibromin is the encoded gene product of the tumor suppressor gene NF1, 
the gene implicated in Neurofibromatosis type 1.
Cancer-associated RAS mutations typically alter amino acids G12, G13 or Q61. 
These mutant RAS proteins display impaired GTPase activity which renders them 
resistant to GTPase activating proteins (GAPs). Mutant RAS proteins are therefore 
locked in the signal-transmitting GTP- bound form (the cytosolic ratio of GTP 
is much higher than GDP at 10:1). The active GTP-RAS in turn activates the RAF 
kinase, resulting in a downstream proliferative effect.
The CBL gene (11q23.3) is a proto-oncogene that encodes three distinct homo-
logs which represent the mammalian CBL family of proteins. Members of the 
CBL protein family (Cbl/c-Cbl, Cbl-b, and Cbl-c/Cbl-3) are E3 ubiquitin ligases 
that functions as a negative regulator of many signal transduction pathways by 
promoting degradation by ubiquitination of activated RTKs (and nonreceptor 
tyrosine kinases). Studies in animal models and genetic analyses in human cancer 
have firmly established that CBL proteins function as tumor suppressors. The 
mutant CBL (lacking E3 ligase activity)- dependent oncogenesis is driven by loss of 
ubiquitination-dependent degradation of activated RTKs resulting in a synergistic 
increase in signaling. Mutant CBL proteins may indeed promote oncogenesis in 
JMML via the RAS signaling pathway. In addition, CBL is an adaptor protein that 
positively regulates signal transduction. Approximately 150 proteins are associated 
with or are regulated by CBL proteins. Among these proteins is the adaptor GRB2 
that binds to CBL. The CBL-GRB2 interaction modulates the interaction between 
GRB2 and SOS and hence it is also possible that CBL-GRB2 interactions lead to 
activation of the RAS pathway.
5.2 GM-CSF–dependent hypersensitivity
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and the related 
cytokines interleukin 3 (IL-3) and interleukin 5 (IL-5) regulate hematopoietic 
cell survival, proliferation, differentiation, migration, and perform effector 
functions such as phagocytosis or reactive oxygen species release. Unlike other 
cytokine receptors, GM-CSF receptor (GMR) has a significant nonredundant role 
in macrophage-mediated acute and chronic inflammation, pulmonary homeostasis, 
allergic diseases, and myeloid haematologic malignancies [13]. GMR is found in 
myeloid cells and some non-hematopoietic cells, but it is not expressed by lymphoid 
cells such as T cells. GMR is composed of a ligand-specific α chain (GMR α) and a 
β common (βc) signaling subunit, which is shared with the IL-3 and IL-5 recep-
tors. Both of which are members of the cytokine receptor family. The binding of 
GM-CSF to the ligand specific GMRα promotes the formation of a higher-order 
signaling complex that leads to the activation of non-receptor tyrosine kinases JAK2 
and Src family kinases (c-Src and Lyn), which subsequently phosphorylate GMRβc 
to create docking sites for adapters and signal relay molecules (such as SHP-2) 
initiating downstream signaling. GM-CSF, IL-3, and IL-5 activate at least three 
downstream pathways: the JAK/STAT pathway, the RAS signaling pathway, and PI 
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3-kinase activation pathway. These pathways should not be viewed as being mutu-
ally exclusive and may have substantial overlap [14].
RAS signaling pathway mutations might potentiate JAK/STAT signaling by 
stabilizing or directly activating the GM-CSF receptor or its associated signaling 
molecules. In particular, the dysregulated SHP-2 (a non-receptor protein tyrosine 
phosphatase) by JMML-associated mutations is normally essential for efficient 
STAT5 activation in myeloid cells that are stimulated with IL-3 (SHP-2 is recruited 
to phosphorylated tyrosine residues on the activated β subunit of the GMR). 
Elevated levels of RAS-GTP might also increase the degree and/or duration of 
JAK2 kinase activity. The disturbed GMR signaling in JMML leads to an aberrant 
response to GM-CSF which can be tested by 2 laboratory assays:
5.2.1 CFU-GM assay (the traditional methylcellulose assay)
The selective hypersensitivity of myeloid progenitor cells of JMML to the 
GM-CSF in hematopoietic colony formation assays (CFAs) results in spontane-
ous growth of colony-forming units -granulocyte/macrophage (CFU-GM) in the 
absence of exogenous growth factors. JMML cells are cultured in semisolid meth-
ylcellulose media producing excess number of monocyte–macrophage colonies in 
the absence of added exogenous growth factors. This spontaneous proliferation of 
JMML myeloid progenitor cells is primarily due to the striking hypersensitivity of 
progenitors to GM-CSF in vitro.
This phenomenon, and hallmark of the disease, was first described in 1991. 
The CFU-GM assay has 2 main pitfalls. The assay is not standardized across diag-
nostic laboratories and although sensitive it is rather a non-specific assay. Viral 
infections such as HHV-6 and CMV have also been reported to cause GM-CSF 
hypersensitivity. Although the hypersensitive pattern of CFU-GM colony growth 
in methylcellulose is neither necessary nor sufficient to establish a diagnosis 
of JMML, it used as a minor diagnostic criterion for those 10 percent of JMML 
patients who do not have identifiable molecular abnormalities affecting the RAS 
signaling pathway.
5.2.2 p-STAT5 phospho-specific flowcytometry assay
Low-dose GM-CSF can induce hyperphosphorylation of STAT5 in either CD33+/
CD34+ (myeloid precursor cells) or CD33+/CD34−/CD14+/CD38low population 
(represents the more mature monocytic cells) in patients with JMML. In contrast 
to CD34+/CD33+ cells, neither CD34−/CD33+ (mature myeloid cells) nor CD34+/
CD33− (non-myeloid precursors), demonstrated any STAT5 hyperphosphorylation 
in response to GM-CSF. These results indicate that the peculiar STAT5 hyperphos-
phorylation signature specifically resides in the myeloid compartment of hemato-
poietic progenitor cells [15].
After binding of GM-CSF to its receptor, Janus-kinase-2 (JAK-2) is recruited 
to the cytoplasmic domain of the β chain, and activation of JAK-2 occurs, 
which subsequently induces STAT-5 phosphorylation. This signaling pathway 
induces migration of STAT-5 dimers to the nucleus and promotes the transcrip-
tion of various genes such as pim-1 and CIS to induce cell differentiation. This 
cytokine-specific response is exclusively present in JMML patients compared 
with healthy controls or other pediatric MPNs, indicating that it is critical for 
disease pathogenesis. The aberrant response of phospho-STAT5 (p-STAT5) to 
sub-saturating doses of GM-CSF is demonstrated by phospho-specific flow-
cytometry assay. This assay is superior to the traditional CFU-GM assay in the 
following aspects [16]:
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1. As compared to CFU-GM assay, p-STAT5 profiling is a rapid diagnostic tool 
for JMML. CFU-GM assay takes up to several weeks of culture as it requires 
monocyte depletion.
2. p-STAT5 profiling could discriminate JMML from diseases mimicking JMML, 
such as CMV infection and transient myeloproliferative disorder in Noonan 
syndrome (NS/MPD) that also exhibit GM-CSF hypersensitivity by in vitro 
colony assay but not by phospho-specific flowcytometry.
Interestingly, CMML (the adult equivalent of JMML) also displays GM-CSF- 
dependent hypersensitivity. Primary CMML samples demonstrate GM-CSF–
dependent hypersensitivity by hematopoietic CFAs and phospho-STAT5 (pSTAT5) 
flowcytometry compared with healthy donors. Among CMML patients, the pSTAT5 
hypersensitive response positively correlated with high-risk disease, peripheral 
leukocytes, monocytes, and signaling associated mutations.
The p-STAT5 response to low doses of GM-CSF was also detectable in AML M4/
M5. JMML, CMML, and M4/M5 AML are related entities in which hyperactive RAS 
and aberrant JAK2/STAT5 signaling are early or initiating events. As such, M4/M5 
AML might be distinct from other subtypes of AML, in which aberrant transcrip-
tion factor fusions such as PML-RARA and AML1-ETO likely represent primary 
leukemogenic events. This has important therapeutic implications, as M4/M5 AML 
might be highly dependent on RAS and JAK2/STAT5 signaling, and therefore sensi-
tive to inhibitors of these pathways. Because GM-CSF signaling is critical for mono-
cyte differentiation and survival, targeting GM-CSF in the therapeutics of JMML in 
vitro and AML in vivo has been reported, with varying degrees of success [17].
The absence of the p-STAT5 phospho-flow signature in conditions that are phe-
notypically similar to JMML highlights the importance of the signaling disruptions 
that we observe specifically in JMML. The flow cytometric p-STAT5 profiling is a 
reliable, sensitive and specific diagnostic tool for identifying patients with JMML 
that was added in the 2016 revision to the World Health Organization classification 
of myeloid neoplasms and acute leukemia as a minor diagnostic criterion for those 
10 percent of JMML patients who do not have identifiable molecular abnormalities 
affecting the RAS signaling pathway.
In fact, hyperphosphorylation of STAT5 does not only add to the genetic map-
ping of JMML but it has significant therapeutic implications. Kotecha et al. dem-
onstrated that p-STAT5 phospho-flow signature may identify children with NRAS 
and PTPN11 mutations who will have a benign clinical course and can be observed 
closely without aggressive treatment. p-STAT5 phospho-flow signature was also 
absent in infants with NS/MPD which indicates that phospho-flow cytometry 
provides a more specific readout of the rewired signaling networks found in JMML. 
Remarkably, p-STAT5 signaling response can indicate disease status as the p-STAT5 
responsive population was shown to disappear in remission and reappear during 
relapse. Differences in GM-CSF-stimulated phospho-STAT5 levels might be utilized 
to identify targeted agents with potential efficacy as well as to follow response to 
treatment, relapse, or transformation to AML [18].
5.3 JMML interlacing with RASopathies
As opposed to the somatic mutations found in cancer, germline mutations of 
genes that encode components or regulators of the RAS signal transduction pathway 
result in clinically defined group of human genetic syndromes collectively termed 
as “RASopathies” or “neuro- cardio-facio cutaneous syndromes (NCFCS) [19]. The 
RASopathies are one of the largest known groups of malformation syndromes with 
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an incidence of around 1 in 1000 individuals. They exhibit numerous overlapping 
phenotypic features such as neurodevelopmental dysmorphic features, an increased 
risk of autoimmunity and predisposition to cancer and abnormal myelopoiesis in 
infancy. The RAS signal transduction pathway plays an essential role in regulating 
the cell cycle and cellular growth, differentiation, and senescence, all of which 
are critical to normal development. Therefore, it is not surprising that RAS signal 
transduction pathway dysregulation has detrimental effects on both embryonic and 
later stages of development. RASopathies include:
1. Noonan syndrome: PTPN11, KRAS, SOS1, RAF1, NRAS.
2. Costello: HRAS.
3. Cardiofacio-cutaneous syndromes (KRAS, BRAF, MEK1/2).
4. Neurofibromatosis type 1: NF1.
5. NS-like syndromes: CBL-syndrome (CBL) and NS-like disorder with loose 
anagen hair (SHOC2).
6. Legius syndrome (NF-1-like syndrome): SPRED1.
Noonan syndrome (NS) is the most genetically diverse and most common 
RASopathy occurring in 1 of 1000 to 2500 births. NS is characterized by develop-
mental disorders, short stature, a typical facial appearance (facial dysmorphism), 
congenital heart defects, and skeletal anomalies. So far, heterozygous mutations in 
nine genes (PTPN11, SOS1, KRAS, NRAS, RAF1, BRAF, SHOC2, MEK1 and CBL) 
have been documented to underlie this disorder or clinically related phenotypes. 
Germline mutations in the PTPN11 gene have been described in 50% of the Noonan 
syndrome cases. Somatically acquired JMML-associated PTPN11 mutations are not 
seen in NS. Somatic mutations differ from germline PTPN11 mutations which are 
predicted to result in a weaker gain-of-function than the somatic mutations [20].
The most common hematopoietic disorder in NS is a transient myeloprolifera-
tive disorder (MPD) estimated to occur in up to 10% of all children with NS. Nearly 
all patients with NS/MPD have mutations in PTPN11. The transient MPD in Noonan 
syndrome is diagnosed in the neonatal period or early infancy. In contrast to JMML, 
NS/MPD is thought to be of polyclonal origin. It generally resolves spontaneously 
over months or years. However, leukocytosis and tissue invasion by monocytes and 
immature myeloid cells can have deleterious effects. An estimated 10% of cases 
of NS/MPD acquire a cytogenetic abnormality and progress to JMML. Thus, NS/
MPD is a tumor predisposition syndrome and affected patients should be followed 
closely. JMML in PTPN11-mutated NS seems to behave differently from sporadic 
JMML as it occurs at a very young age (infancy) and tends to regress spontaneously. 
Although the hematological picture can be indistinguishable from JMML in some 
cases, the myeloproliferation is polyclonal in most instances, and thus, the disorder 
has not been recognized by the World Health Organization (WHO) as a separate 
JMML category. Therefore, recognizing NS in a JMML patient is important in 
order to identify those patients who might benefit from a watch-and-wait strategy. 
Similar to PTPN11-mutated NS, a transient MPD was noted in some children with 
NS and KRAS or NRAS germline mutations.
NF1 gene is a negative modulator that normally restricts RAS activation. Loss 
of heterozygosity (LOH) with loss of the normal NF1 allele in leukemic cells leads 
to activation of RAS signaling pathway. In most cases, the diagnosis of NF1 can be 
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established clinically by the presence of ≥6 caf ’e au lait macules >0.5 cm in diam-
eter. In addition, one-half of these children have a parent affected by NF1.The risk 
of developing JMML for the patient with NF1 is estimated 200- to 350-fold higher 
than in patients without NF1.
Germ line mutations of the CBL gene cause CBL syndrome characterized by a 
high frequency of neurologic features/vasculopathy, mild NS-like features, and a 
high risk of JMML. The germline mutation represents the first hit, with somatic 
LOH being the second hit positively selected in JMML cells. Indeed, all children 
with JMML and CBL mutations were found to have a germline CBL missense 
mutation on one allele and acquired LOH on the other allele in leukemic cells. The 
development of vasculopathies occurs in the second decade of life unless allogeneic 
HSCT is successful. The most frequently observed vasculopathies are optic atrophy, 
optic neuritis, hypertension, cardiomyopathy, and arteritis.
5.4 Cytogenetic studies
JMML cells show a normal karyotype in 65% of cases, sole monosomy 7 in about 
25%, and other aberrations in 10%. A remarkable feature of many JMML cases with 
normal karyotype is a markedly increased synthesis of fetal hemoglobin (HbF). 
The likelihood of an abnormal karyotype is dependent on the genetic subtype, 
with monosomy 7 being noted most often in KRAS-mutated disease. Monosomy 7 
is the most frequent chromosomal aberration in both MDS and JMML. It is likely 
that haploinsufficiency of genes located on chromosome 7 contributes to clonal 
evolution.
6. JMML genetic subtypes
Deregulated RAS signaling is the main driving event in JMML. The 5 canonical 
RAS pathway mutations (PTPN11, KRAS, NRAS, CBL, and NF1 genes) repre-
sent five genetically and clinically distinct subtypes in JMML. Mutations in the 
respective genes can either occur as germline (“syndromic”) or as somatic lesion 
in hematopoietic cells (“nonsyndromic”). PTPN11-, NRAS-, and KRAS-mutated 
JMML are characterized by heterozygous somatic gain-of-function mutations in 
nonsyndromic children, whereas JMML in neurofibromatosis type 1 and JMML in 
children with CBL syndrome are defined by germline RAS disease and acquired 
biallelic inactivation of the respective genes in hematopoietic cells. Their clinical 
features are presented in Table 2.
The concept that mutations associated with JMML are mutually exclusive within 
a given individual implies that a mutation in any one of these genes is sufficient to 
activate the signaling pathway and drive the proliferation of JMML cells. However, 
this does not mean that two or more genetic mutations cannot occur at the same 
time as one would comprehend from the term ‘mutually exclusive’. In fact, coexist-
ing mutations in NRAS, KRAS, PTPN11, CBL and NF1 were found in 11% of JMML 
patients [21]. Analysis of single colonies for two patients with compound RAS 
pathway mutations demonstrated that both mutations occurred in the same colony. 
PTPN11 and NF1 lesions were the most frequent of these cooperative events. In 
addition, one patient harbored two NRAS lesions (p.G13D and p.Q61K).
The five JMML genetic subtypes are key determinants for treatment adapta-
tion in patients with JMML. However, their use in a risk stratification algorithm is 
hindered by their failure to independently prognosticate the clinical outcome. In 
fact, the prognostic relevance is owned by the number of mutations at diagnosis 









• Incidence: 5–10% of cases.
• Higher platelet count.
• Higher percentage of blasts in bone marrow.
• More often diagnosed after the age of 5 years than other subtypes.
• Although some of the younger children can initially enjoy a relatively unaffected 





• Incidence: 35% of cases.
• A rapidly fatal disorder unless allogeneic HSCT can successfully be performed.
• Significantly worse outcome with higher probability of relapse rates when 
compared with other subtypes.
• Frequent acquisition of NF1 haploinsufficiency.




• Incidence: 18% of cases.
• A heterogeneous course.
• A considerable percentage of patients relapse after HSCT (typically older 
children with high levels of HbF).
• Some patients enjoy an indolent course with spontaneous regression (typically 
infants or cases with G12S mutation). Clinically, these children are well and show 




• Incidence: 14% of cases.
• Most children are diagnosed below the age of 1 year (i.e, infants). They often 
 present with particularly severe disease.
• Monosomy 7 is frequently noted in leukemic cells.
• In some cases, an impressive treatment response to azacitidine has been observed.
• Although Aggressive at presentation, KRAS-mutated JMML has a low relapse rate 
after allogeneic HSCT and may benefit from less intensive preparative regimens.




• Incidence: 12 to 18% of cases.
• Patients display several congenital anomalies that overlap with those observed in 
NF-1, NS, and Legius syndrome.
• Self-limiting disease: most children experience spontaneous regression of their 
myeloproliferation despite the persistence of LOH of the CBL locus in hematopoi-
etic cells.
• Observation without therapeutic intervention is generally advised, but in some 
instances grossly enlarged spleens and thrombocytopenia require therapeutic 
intervention.
• The value of allogeneic HSCT is uncertain.
• Frequent occurrence of partial rejection with stable mixed chimerism after 
allogeneic HSCT.
• The only recurrent variant is copy-neutral isodisomy (LOH) at 11q23.3 where CBL 
is located. No other concomitant mutations are found.
Table 2. 
Clincal features of genetic subtypes of JMML.
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more somatic mutations at diagnosis have significantly worse event-free and overall 
survival rates than those with one or no event. In harmony with these findings, the 
known clinical risk factors predictive of poor outcome (Table 3) are only weakly 
associated with the type of index mutation but they would rather fit patients with 
two or more underlying somatic mutations.
In addition to the mutations in RAS pathway genes (PTPN11, NRAS, KRAS, 
CBL, or NF1), other driver mutations thought to be the initiating events of JMML 
have been recently identified such as RRAS, RRAS2, or SH2B3 mutations. RRAS 
and RRAS2 genes are both members of the RAS GTPase family and hence expanded 
the spectrum of RAS pathway mutations in JMML. Activating mutations in RRAS 
underlie a phenotype within the RASopathy spectrum. Children with RRAS-
mutated JMML can have an atypical clinical course with rapid progression to AML 
[22]. Somatic RRAS mutations co-occurred with acquired NRAS lesions in atypical 
JMML characterized by late onset and rapid progression to AML as well.
7. Secondary genetic mutations in JMML
In addition to the initiating canonical RAS pathway mutations, secondary clonal 
abnormalities were detected in about one-half of the patients. The importance of 
these mutations relies in how secondary mutations alter the behavior of cells in 
contrast to cells harboring only the primary lesion. Secondary mutations are often 
subclonal and may be involved in disease progression rather than initiation of leu-
kemia. It appears that such mutations characterize patients with the highest risk of 
progression and poor outcome. The acquisition of the second mutation would thus 
also explain the continuum between RALD and leukemia. The clone harboring the 
secondary event frequently expands at the time of relapse post HSCT. This phenom-
enon has important therapeutic implications. Combination of therapies with agents 
that target the RAS pathway as well as the secondary genetic event could prove 
more efficacious in the correct genetic context than monotherapy alone.
The secondary mutational events occur inside or outside the canonical RAS 
pathway axis. They include second hits targeting the RAS pathway (so-called ‘RAS 
double mutants’) as well as mutations in SETBP1, JAK3, SH283, components of the 
polycomb repressive complex 2 (like EZH2 and ASXL1), and occasionally, spliceo-
some genes. Some authors linked differential expression of key regulatory noncod-




2- Platelet count ≤ 40 x 109/L.
3- Increased fetal hemoglobin (HbF) for age.
4- Male sex (in some references).
Molecular risk 
factors:
1- Two or more somatic mutations.
2- Secondary genetic mutations.
3- DNA hypermethylation signature defines an aggressive JMML subgroup with 







of JMML [23]. Secondary mutations of SETBP1 and JAK3 were the most frequent 
mutations (around 15% of children) and were presumed to be involved in tumor 
progression and poor clinical outcomes.
8. Epigenetic landscape of JMML
Aberrant DNA methylation was found to be an initiating event in JMML. This 
finding has instigated the research in the field of epigenetics and led to the land-
mark discovery of methylation classes in 2017. In addition, epigenetic modifications 
are implicated in JMML disease progression and together with established clinical 
and genetic markers fully recapitulate the clinical and biological heterogeneity of 
JMML. The genome-wide DNA methylation analysis of JMML patients identified 
three biologically distinct JMML subgroups [24]:
1. The high-methylation group (HM) was dominated by older children and cases 
with somatic PTPN11 mutations and poor clinical outcome.
2. The intermediate methylation group (IM) showed enrichment for somatic 
KRAS mutations and monosomy 7.
3. The low methylation group (LM) is enriched for somatic NRAS and CBL 
 mutations, as well as for Noonan patients, and has a good prognosis.
The results of all DNA methylome studies in JMML were exceptionally consis-
tent with the fact that DNA hypermethylation is a recurrent feature of JMML cells 
that confers treatment resistance. The dysregulated genomic DNA methylation is a 
crucial component of RAS-driven malignant cell transformation proposing a possible 
functional links between RAS pathway mutational patterns and methylation classes. 
However, DNA hypermethylation was only weakly associated with the canonical 
genotypes or cytogenetic aberrations. Instead, it correlated strongly with the known 
clinical risk factors predictive of aggressive disease and poor outcome, especially 
older age and increased HbF level (Table 3). In fact, DNA methylation status is an 
independent prognostic factor and better predictor of clinical outcome than JMML 
genetic types. Frequent hypermethylation in 4 genes (BMP4, CALCA, CDKN2B, and 
RARB) were associated with a poor prognosis. Moreover, RASA4 hypermethylation 
was related to poor prognosis and disease relapse after HSCT. DNA methylation 
could be used as a biomarker that can both identify patients who are predicted to fail 
HSCT as well as those who are most likely to experience spontaneous  resolution and 
could be observed to avoid the acute and late side effects of HSCT [25].
9. Treatment
The heterogeneity of the disease is reflected by the varied clinical outcomes. 
Although the current standard of care for JMML is allogeneic HSCT, continued 
controversy exists about identifying those patients who need to be moved quickly 
to HSCT versus those rare patients who might be observed [26]. The majority of 
children with CBL-mutated JMML and some NRAS- mutated patients experience 
spontaneous disease regression. These children are clinically well with a low HbF. A 
careful watch-and-wait strategy may be indicated as the treatment of choice. On the 
other hand, JMML with somatic PTPN11 mutations appear to represent cases with 
aggressive biology with a high risk of relapse even after HSCT.
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Nevertheless, allogeneic HSCT remains the most effective means of stopping 
the uncontrolled production of monocytic cells in the majority of patients. If left 
untreated, survival for most children is less than one year. The predominant cause 
of JMML-related death is respiratory failure as a result of pulmonary infiltration 
by leukemic cells (blastic transformation is infrequent in JMML). In fact, HSCT 
early in the course of disease significantly improved the dismal prognosis of JMML 
patients. However, the 5-year event-free survival (EFS) rate after HSCT is only 
44–53%. Disease recurrence is the most important cause of failure, occurring with 
a cumulative incidence of 35%. Of note, patients with JMML who transform into 
AML (defined as >20% blasts in bone marrow) generally have dismal outcomes 
following HSCT.
Pre-transplant chemotherapy for JMML had no benefit on EFS or overall sur-
vival. A variety of pre-HSCT treatments have been employed to control symptoms 
of JMML (such as high white blood cell count, pulmonary problems, and/or promi-
nent organomegaly) as well as theoretically improve outcomes. However, none of 
these agents induced durable responses or reduced the relapse rate. The main aim 
of the pre-HSCT treatments remains to bridge HSCT. Given the current lack of 
convincing evidence for traditional myelosuppressive chemotherapy pre-HSCT, 
other treatment modalities has been sought. In particular, molecular classifica-
tion of cancer based on DNA methylomes has revolutionized the diagnostic and 
prognostic parameters of JMML and aid our understanding of the mechanistic link 
between epigenetic dysregulation and resistance to treatment. A DNA methyltrans-
ferase–inhibiting azanucleoside is assumed to reverse the epigenetic dysregulation 
in malignant cells. This has led to a European protocol to employ DNA hypometh-
ylating agents such as azacitidine for therapy in JMML [27]. The first case report 
of azacitidine for JMML before HSCT was published in 2009. The child achieved a 
complete clinical, hematologic, cytogenetic (monosomy 7) and molecular (KRAS 
index mutation) remission during eight monthly cycles of 5-day azacitidine. The 
reduction of BMP4 promoter DNA methylation preceded the disappearance of 
leukemic cells, demonstrating the DNA-hypomethylating activity of azacitidine in 
JMML cells. Although azacytidine may induce complete clinical, cytogenetic and/or 
molecular remission before allogeneic HSCT, complete remission has not been sus-
tained without transplant. On the other hand, the acceptable toxicity of low-dose 
azacitidine and its cytoreductive potential make it an attractive option as a bridging 
therapy before HSCT or as palliation after 1 or more transplants have failed [28].
10. Conclusion and future perspectives
JMML is a puzzling disease with blurring clinical presentation that can com-
monly mimic a wide variety of other diseases. Overall, the most consistent features 
of the JMML phenotype are young patient age, splenomegaly and increased syn-
thesis of hemoglobin F (HbF). The molecular basis of JMML is closely linked to 
Rasopathies, a family of inherited cancer predisposition syndromes characterized 
by cardiac defects, defective growth, facial dysmorphism and variable cognitive 
deficits. Defining aberrant RAS signaling transduction pathway as the common 
denominator linking RASopathies to JMML and a transient JMML-like disease 
made JMML a fundamentally a disease of uncontrolled hyperactivation of RAS 
signaling. The identification of RAS pathway mutations in JMML has advanced 
the understanding of molecular mechanisms underlying the progression from 
cancer predisposition to neoplasia. Deciphering of the mutational spectrum had 
led to the classification of JMML into 5 genetic subtypes which have distinctive 
genotype–phenotype characteristics. However, the clinical outcome of JMML 
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is not completely explained by the clinical and genetic markers which lent the 
epigenetic landscape of JMML a particular interest. There is hardly any pediatric 
oncology entity where research has benefited as much from epigenetics as JMML. 
Genome-wide interrogation of DNA methylation patterns has led to a classification 
of the disease into three distinct JMML subgroups that have clear pathogenetic and 
prognostic relationships. The DNA hypermethylation signature is associated with 
poor clinical outcome and increased risk for relapse following HSCT. Evidence 
suggests that DNA methylation changes could be used as a potential biomarker in a 
combined risk stratification algorithm in future clinical trials. Although the clinical 
activity of azacitidine as a DNA hypomethylating agent appears to be promising, 
it is unlikely that azacitidine alone have the potential to cure JMML [29]. However, 
azacitidine as monotherapy is safe and effective in controlling disease both in 
upfront and relapsed patients in order to proceed to HSCT [30]. In fact, azacitidine 
is currently the gold standard bridge to HSCT in JMML.
Despite the lack of associated mutations in the genes coding for the GMR, 
JMML is characterized by aberrant GMR signal transduction. This aberrant 
signaling is integral in the pathogenesis of JMML that underlines the dysregulated 
myelopoiesis of the disease. The resultant selective GM-CSF hypersensitivity was 
exploited as a diagnostic tool for JMML and it is especially useful for those diagnos-
tically challenging cases with RAS pathway mutation-negative JMML. This entity 
represents the remaining 10% of cases where disease might be due to chromosomal 
translocations, other gene mutations, specific microRNAs (miRNA) or long non-
coding RNAs (lncRNAs) [31]. GMR signal transduction is located upstream to both 
RAS signaling pathway and the JAK/STAT pathway. STAT5 is recruited to phos-
phorylated tyrosine residues on the activated β subunit of the GM-CSF receptor, 
indicating that STAT5 signaling profile reflects JMML hypersensitivity to GM-CSF. 
The p-STAT5 phospho-specific flowcytometry assay which largely replaced the tra-
ditional colony assay had also recently gained promising utility in monitoring the 
disease status. As disease worsens, a greater percentage of cells get hyper-respon-
sive. Therefore, p-STAT5 phospho-flow signature could prove enticing as a marker 
of disease progression and indicator of relapse. As JMML lacks tractable markers, 
both DNA methylation and p-STAT5 phospho-flow signature are potential new 
armamentarium that could serve as futuristic checkpoints in order to promulgate 
uniform protocols designed to follow patients on therapy. Interestingly, the shared 
p-STAT5 phospho-flow signature in JMML, AML M4/M5 and CMML could explain 
the unique overlap of their clinical features.
So far HSCT represents the only therapy with a clear impact on the outcome of 
JMML patients. However, HSCT is replete with significant morbidities and deleteri-
ous late effects in this young population. The search for more effective and less toxic 
strategies coincided with advances in molecular oncology that opened up a realm 
of novel and targeted molecules capable of improving therapeutic tactics in JMML. 
In particular, scoping into the genetic basis of hyper-responsiveness in JMML could 
provide a means of assessing the efficacy of emerging kinase inhibitors such as 
those blocking the RAS (e.g., the oral MEK inhibitor trametinib) or JAK2-signaling 
pathways for the treatment of this disease. Notably, a combination of drugs target-
ing two different pathways might be more effective than a single drug. However, the 
choice of drugs used for treatment should be entirely based on patient’s mutation 
status [32, 33].
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